PharmTech Drug Digest 11.20
News|Articles|July 24, 2017

GE, Oritain Partner on Bovine Serum Traceability

GE Healthcare partners with Oritain for an independent test that can confirm the country of origin of fetal bovine serum (FBS), a component of biopharmaceutical production.

GE Healthcare and Oritain, a New Zealand-based company specializing in the scientific verification of food origins, have launched an independent test-based traceability program to authenticate the country of origin of fetal bovine serum (FBS), a cell growth supplement used for manufacturing biopharmaceuticals and vaccines. FBS is also used in basic research and drug discovery. The country of origin is important because FBS is used in biomanufacturing, and different countries pose different risk levels for virus contamination. Using FBS from low-risk countries is a priority in biomanufacturing.

GE is currently traceability-certified by the International Serum Industry Association. To verify that raw serum from Australia, New Zealand, and the United States is from that country of origin, GE will also put its sera products through a testing process that goes beyond industry-standard traceability practices. With GE’s new testing program, Oritain will perform independent testing on FBS batch samples from Australia, New Zealand, and the US. Oritain’s scientific traceability method does not rely on paper or labels, but rather authenticates the origin of the product itself, according to Oritain in a company press release. 

Source: GE


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.